Search - tctmd.com

Displaying 1 - 20 of 31

Sort: Relevancy | Date

Patchy Anticoagulation Use During COVID Pandemic Raises Questions

News Daily News

Patchy Anticoagulation Use During COVID Pandemic Raises Questions

March 06, 2025

CV Risk After Acute COVID-19 Not So High as Feared: Registry

News Daily News

CV Risk After Acute COVID-19 Not So High as Feared: Registry

January 06, 2023

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

News Conference News AHA 2022

‘Agnostic’ EHR Alerts Boost VTE Prophylaxis in Hospitals and Postdischarge

November 11, 2022

Study Affirms Higher CVD, Mortality Risks Among COVID-Positive Patients

News Daily News

Study Affirms Higher CVD, Mortality Risks Among COVID-Positive Patients

October 26, 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

News Conference News ESC 2022

COVID-PACT: Full-Dose Anticoagulation Improves Outcomes in Critical COVID-19

September 01, 2022

CVD, Diabetes Spike in Acute Phase of COVID-19

News Daily News

CVD, Diabetes Spike in Acute Phase of COVID-19

July 19, 2022

COVID-19: TCTMD’s Dispatch for June Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for June Week 3

June 13, 2022

Mystery MINOCA? Many COVID STEMIs Have No Culprit Lesion

News Conference News SCAI 2022

Mystery MINOCA? Many COVID STEMIs Have No Culprit Lesion

May 19, 2022

COVID-19: TCTMD’s Dispatch for March Week 3

News Daily News

COVID-19: TCTMD’s Dispatch for March Week 3

March 14, 2022

Hearts, Lungs, Kidneys: Mild-to-Moderate COVID-19 Leaves a Mark

News Daily News

Hearts, Lungs, Kidneys: Mild-to-Moderate COVID-19 Leaves a Mark

January 14, 2022

Pandemic Blamed for Loss of BP Control That Has Not Fully Rebounded

News Conference News AHA 2021

Pandemic Blamed for Loss of BP Control That Has Not Fully Rebounded

November 18, 2021

COVID-19: TCTMD’s Dispatch for November Week 1

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 1

November 01, 2021

Antithrombotic therapy does not provide a benefit for clinically stable but symptomatic outpatients with COVID-19, published results of the ACTIV-4b trial affirm. Neither aspirin nor apixaban (Eliquis; Bristol Myers Squibb) at prophylactic or therapeutic doses reduced what were already very low rates of major adverse cardiopulmonary outcomes versus placebo, and both modestly increased bleeding, researchers led by Jean Connors, MD (Brigham and Women’s Hospital, Boston, MA), report in a paper published online

News Daily News

ACTIV-4b: No Antithrombotic Therapy Needed for COVID-19 Outpatients

October 13, 2021

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

News Daily News

HEP-COVID: Therapeutic-Dose Heparin Effective in Non-ICU Patients

Yael L. Maxwell

October 12, 2021

COVID-19: TCTMD’s Dispatch for September Week 5

News Daily News

COVID-19: TCTMD’s Dispatch for September Week 5

September 27, 2021

Score May Help Guide VITT Management After COVID-19 Vaccination

News Daily News

Score May Help Guide VITT Management After COVID-19 Vaccination

September 23, 2021

Rare Clotting Complication Seen After mRNA Vaccine: Case Report

News Daily News

Rare Clotting Complication Seen After mRNA Vaccine: Case Report

June 28, 2021

CVST Risk Far Lower With Viral-Vector Vaccines Than With COVID-19 Itself

News Daily News

CVST Risk Far Lower With Viral-Vector Vaccines Than With COVID-19 Itself

June 10, 2021

COVID-19: TCTMD’s Daily Dispatch for June Week 2

News Daily News

COVID-19: TCTMD’s Daily Dispatch for June Week 2

June 07, 2021

ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19

News Conference News ACC 2021

ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19

May 17, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.